Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

20 August 2009 Filed under Cancer, Denosumab, Hormonal-ADT, Osteoporosis, Prostate Cancer, Side Effects, trial results Posted by » Comments Off

Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. Matthew R. Smith and an international team investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. In today’s New England Journal of Medicine, August 20, they report positive results:

In this double-blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 months or placebo (734 patients in each group). The primary end point was percent change in bone mineral density at the lumbar spine at 24 months. Key secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures.

Results At 24 months, bone mineral density of the lumbar spine had increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P<0.001); significant differences between the two groups were seen at as early as 1 month and sustained through 36 months. Denosumab therapy was also associated with significant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius at all time points. Patients who received denosumab had a decreased incidence of new vertebral fractures at 36 months (1.5%, vs. 3.9% with placebo) (relative risk, 0.38; 95% confidence interval, 0.19 to 0.78; P=0.006). Rates of adverse events were similar between the two groups.

Conclusions Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.

SOURCE: NEJM Aug 20, 2009.

Earier related:
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(®)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Who Continued on Alendronate Amgen press release. Sept 15 2008.

Tags:

Trackback URL

Comments are closed.